Watchdog says benefits outweigh risks but that warning should be added to product information
Europe’s medicines regulator has found a possible link between Johnson & Johnson’s coronavirus vaccine and very rare cases of unusual clotting disorders that prompted authorities in Europe and the US to pause the shot’s rollout last week.
The Amsterdam-based European Medicines Agency (EMA) said in a statement on Tuesday its safety committee had concluded a warning should be added to the vaccine’s product information, but that the shot’s benefits outweighed its risks.
